Yes, Tezspire (tezepelumab) is a biologic. It is a fully human monoclonal antibody approved by the FDA for the add-on maintenance treatment of severe asthma in adults and children aged 12 and older. What makes it unique among asthma biologics is where it acts in the inflammatory chain: it blocks a signaling protein called TSLP, which sits further upstream than the targets of other biologic options.
What Makes Tezspire a Biologic
Biologics are medications made from living cells rather than synthesized through chemistry. Tezspire is produced in Chinese hamster ovary cells using recombinant DNA technology, which is standard for monoclonal antibodies. Because it’s a large, complex protein, it can’t be taken as a pill. It has to be injected subcutaneously (under the skin) so the protein reaches the bloodstream intact.
This living-cell origin is what distinguishes biologics from conventional drugs. It also means there’s some potential for your immune system to recognize the protein as foreign and develop antibodies against it. In clinical trials, about 5% of asthma patients developed these anti-drug antibodies, though this didn’t appear to significantly affect how well the medication worked.
How Tezspire Works Differently Than Other Biologics
Five biologics are currently approved for severe asthma, and each targets a different point in the inflammatory process. Most of them block signals that are already partway down the chain:
- Omalizumab (Xolair) blocks IgE, the antibody responsible for allergic reactions on mast cells and other immune cells.
- Mepolizumab (Nucala) and benralizumab (Fasenra) target IL-5 or its receptor, reducing eosinophil levels.
- Dupilumab (Dupixent) blocks IL-4 and IL-13 signaling, which drive both eosinophilic and allergic inflammation.
Tezspire works higher up. TSLP is a protein released by damaged airway cells when they encounter allergens, viruses, pollution, or even mechanical irritation. Once released, TSLP kicks off a cascade that activates immune cells, triggers the production of IL-4, IL-5, and IL-13, promotes IgE production, and recruits eosinophils into the airways. By neutralizing TSLP before it can bind to its receptor, Tezspire essentially shuts down this cascade at its starting point rather than intercepting individual branches further downstream.
Why the “Upstream” Target Matters
Most asthma biologics work best in patients with clearly elevated type 2 inflammatory markers, things like high blood eosinophil counts or elevated IgE. Tezspire’s broader mechanism gives it an edge in a specific way: clinical trials showed benefit in patients with both high and low eosinophil counts.
In the NAVIGATOR trial, Tezspire reduced asthma flare-ups by 56% overall compared to placebo. Patients with higher eosinophil levels saw the greatest benefit, but even those with low eosinophil counts (below 150 cells per microliter) still experienced a 39% reduction. This is significant because there are currently no other approved biologics for severe asthma that isn’t driven by type 2 inflammation, a category that represents a meaningful portion of people with severe disease. Tezspire doesn’t require specific biomarker levels for prescribing, which sets it apart from most other options.
How It’s Given
Tezspire is a 210 mg injection given once every four weeks. It comes in a pre-filled syringe (for clinic use) and a pre-filled pen designed for home use. After your healthcare provider confirms it’s appropriate and you’ve been trained on the injection technique, you or a caregiver can administer it at home with the pen. The injection goes under the skin, typically in the thigh or abdomen.
Common Side Effects
Tezspire’s side effect profile in clinical trials was relatively mild. The most common reactions in asthma patients were sore throat (pharyngitis) at about 4%, joint pain at 4%, and back pain at 4%. Injection site reactions occurred in roughly 5-6% of patients using the pre-filled pen. Upper respiratory infections and nasal inflammation were also reported, particularly in patients being treated for chronic sinus issues with nasal polyps, where rates of nasopharyngitis reached 18%.
These numbers were generally close to what patients on placebo experienced, which is part of why Tezspire is considered well-tolerated as biologics go.
Cost and Financial Assistance
Biologic medications are expensive, and Tezspire is no exception. The manufacturer offers two financial support programs through TEZSPIRE Together. If you have commercial insurance that covers Tezspire, the co-pay program can bring your out-of-pocket medication cost to as little as $0 per dose, with up to $100 per month covered for in-office injection administration. There are no income requirements for the co-pay program.
If you’re uninsured, on Medicare Part B without supplemental coverage, or on a Medicare Advantage plan with a significant affordability gap (out-of-pocket costs above $100), a separate patient assistance program may provide Tezspire at no cost. You can reach the support hub at 1-888-897-7473 on weekdays. For patients under 18, a parent or legal guardian can enroll on their behalf.